4519.T Earnings — Chugai Pharmaceutical Co., Ltd.
JPX
Updated
When is 4519.T's next earnings date?
Chugai Pharmaceutical Co., Ltd. (4519.T) has not announced its next earnings date yet. Its most recent earnings report was on Tuesday, October 27, 2026.
How did 4519.T do in its last earnings report?
In its most recent report on Oct 27, 2026, Chugai Pharmaceutical Co., Ltd. posted EPS of $93.08 versus the $76.78 estimate, a beat of 21.2%. Revenue was $405.31B against a $345.62B estimate.
How much does 4519.T stock move after earnings?
4519.T beat EPS estimates in 1 of its last 2 reported quarters.
About Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
🤖 AI Earnings Analysis
4519.T trades at 21.6× earnings with a 34.5% profit margin; absent recent news or guidance data, valuation and profitability are the clearest available signals.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-27 | 76.78 | 93.08 | +21.23% | $405.31B | ✅ Beat | — | — | — | |
| 2026-07-24 | 75.67 | 69.19 | — | $343.59B | ❌ Miss | — | — | — |
Showing last 2 quarters.